InvestorsHub Logo
Followers 827
Posts 119493
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 2812

Friday, 04/12/2019 7:48:00 AM

Friday, April 12, 2019 7:48:00 AM

Post# of 4859
GILD, NVO ink NASH clinical-trial collaboration:

https://finance.yahoo.com/news/gilead-sciences-novo-nordisk-announce-080000276.html

Gilead Sciences and Novo Nordisk…today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a proof of concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of patients with NASH. The companies are also exploring the potential to collaborate on preclinical research to advance understanding of the disease.

Financial details were not disclosed.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GILD News